(Total Views: 315)
Posted On: 04/23/2019 9:00:11 PM
Post# of 72446
The possibilities are endless:
A tier 1 global pharma suggested it - it may or may not be part of a pending deal.
A tier 2 EU pharma suggested it - it may or may not be part of a pending deal.
It may have been suggested in the term sheet - may or may not still be in play.
It was necessary to tie in with the EMA and dual-approval.
I have no doubt it is something a potential partner wants to see.
As for your valuations in another post:
$50M upfront is a solid deal. $1-2 deal.
$100M upfront + trial costs is a bonanza $2+ deal.
A tier 1 global pharma suggested it - it may or may not be part of a pending deal.
A tier 2 EU pharma suggested it - it may or may not be part of a pending deal.
It may have been suggested in the term sheet - may or may not still be in play.
It was necessary to tie in with the EMA and dual-approval.
I have no doubt it is something a potential partner wants to see.
As for your valuations in another post:
$50M upfront is a solid deal. $1-2 deal.
$100M upfront + trial costs is a bonanza $2+ deal.
(0)
(0)
